Stock listing
NASDAQ:RNA Atrium Therapeutics, Inc. Stock
Home listing (NASDAQ) of Atrium Therapeutics, Inc.
Follow Atrium Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RNA
$6.92 USD +0.28 (+4.2%)
Close on Nov 20, 2026
- Day range
- $6.88 – $7.44 USDNov 20, 2026
- Volume
- 319,656 sharesNov 20, 2026
- Market cap
- $118.4M USDAt the close on Nov 20, 2026 · price × 17.11M shares outstanding
- Traded on an average day
- $2.73M USDMedian day 220,812 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RNA · Home | $6.92 USD | +0.28 (+4.2%) | 319,656 | $7.01 | $7.44 | $6.875 | $6.64 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.92 | +0.28 | +4.2% | $7.01 | $7.44 | $6.875 | 319,656 | |
| $6.64 | +0.16 | +2.5% | $6.46 | $6.78 | $6.45 | 220,812 | |
| $6.48 | +0.05 | +0.8% | $6.46 | $6.945 | $6.445 | 352,218 | |
| $6.43 | -1.08 | -14.4% | $7.54 | $7.69 | $6.36 | 337,582 | |
| $7.51 | +0.01 | +0.1% | $7.71 | $7.83 | $7.47 | 195,172 | |
| $7.50 | -0.46 | -5.8% | $7.89 | $7.89 | $7.49 | 294,716 | |
| $7.96 | -0.27 | -3.3% | $8.23 | $8.26 | $7.93 | 130,118 | |
| $8.23 | -0.15 | -1.8% | $8.30 | $8.40 | $8.11 | 108,814 | |
| $8.38 | +0.04 | +0.5% | $8.42 | $8.463 | $8.20 | 138,121 | |
| $8.34 | +0.02 | +0.2% | $8.32 | $8.55 | $8.23 | 108,189 | |
| $8.32 | -0.36 | -4.1% | $8.68 | $8.73 | $8.29 | 193,893 | |
| $8.68 | -0.04 | -0.5% | $8.85 | $8.99 | $8.50 | 136,789 | |
| $8.72 | +0.17 | +2.0% | $8.57 | $8.77 | $8.45 | 280,927 | |
| $8.55 | +0.28 | +3.4% | $8.22 | $8.64 | $8.185 | 470,071 | |
| $8.27 | +0.01 | +0.1% | $8.19 | $8.31 | $7.88 | 566,641 | |
| $8.26 | -0.14 | -1.7% | $8.52 | $8.65 | $8.20 | 155,777 | |
| $8.40 | +0.08 | +1.0% | $8.14 | $8.45 | $8.14 | 233,598 | |
| $8.32 | +0.27 | +3.4% | $8.05 | $8.39 | $8.05 | 198,572 | |
| $8.05 | -0.15 | -1.8% | $8.20 | $8.23 | $7.98 | 187,418 | |
| $8.20 | +0.04 | +0.5% | $8.06 | $8.21 | $7.78 | 192,660 | |
| $8.16 | +0.16 | +2.0% | $8.01 | $8.185 | $7.945 | 173,482 | |
| $8.00 | +0.02 | +0.3% | $7.97 | $8.32 | $7.96 | 193,208 | |
| $7.98 | +0.37 | +4.9% | $7.75 | $8.27 | $7.71 | 289,488 | |
| $7.61 | -0.06 | -0.8% | $7.68 | $7.87 | $7.49 | 243,913 | |
| $7.67 | -0.15 | -1.9% | $7.79 | $8.06 | $7.67 | 190,978 | |
| $7.82 | +0.14 | +1.8% | $7.75 | $7.87 | $7.64 | 131,236 | |
| $7.68 | -0.07 | -0.9% | $7.75 | $7.935 | $7.54 | 269,494 | |
| $7.75 | -0.46 | -5.6% | $8.22 | $8.22 | $7.75 | 237,187 | |
| $8.21 | -0.19 | -2.3% | $8.40 | $8.482 | $8.21 | 87,396 | |
| $8.40 | +0.14 | +1.7% | $8.29 | $8.50 | $8.135 | 208,348 | |
| $8.26 | +0.33 | +4.2% | $8.15 | $8.325 | $7.965 | 649,309 | |
| $7.93 | -0.06 | -0.8% | $7.95 | $8.13 | $7.93 | 91,818 | |
| $7.99 | +0.02 | +0.3% | $8.00 | $8.07 | $7.78 | 411,686 | |
| $7.97 | +0.13 | +1.7% | $7.83 | $8.105 | $7.63 | 268,285 | |
| $7.84 | -0.30 | -3.7% | $8.22 | $8.421 | $7.68 | 533,805 | |
| $8.14 | -0.14 | -1.7% | $8.30 | $8.44 | $7.96 | 395,723 | |
| $8.28 | -0.14 | -1.7% | $8.38 | $8.46 | $8.22 | 197,306 | |
| $8.42 | 0.00 | 0.0% | $8.42 | $8.50 | $8.21 | 158,804 | |
| $8.42 | +0.13 | +1.6% | $8.21 | $8.515 | $8.05 | 504,915 | |
| $8.29 | +0.10 | +1.2% | $8.20 | $8.365 | $8.10 | 221,427 | |
| $8.19 | -0.14 | -1.7% | $8.30 | $8.49 | $8.16 | 355,242 | |
| $8.33 | -0.89 | -9.7% | $9.22 | $9.31 | $8.29 | 434,524 | |
| $9.22 | +0.03 | +0.3% | $9.24 | $9.485 | $9.17 | 241,277 | |
| $9.19 | +0.24 | +2.7% | $8.97 | $9.34 | $8.943 | 481,266 | |
| $8.95 | -0.61 | -6.4% | $9.57 | $9.665 | $8.66 | 1,036,990 | |
| $9.56 | +0.06 | +0.6% | $9.65 | $9.695 | $9.435 | 569,619 | |
| $9.50 | -0.59 | -5.8% | $10.11 | $10.11 | $9.50 | 356,436 | |
| $10.09 | -0.12 | -1.2% | $10.21 | $10.21 | $9.62 | 274,580 | |
| $10.21 | -0.15 | -1.4% | $10.37 | $10.71 | $10.15 | 255,714 | |
| $10.36 | +0.01 | +0.1% | $10.37 | $10.41 | $10.00 | 247,499 | |
| $10.35 | -0.16 | -1.5% | $10.44 | $10.74 | $10.28 | 421,628 | |
| $10.51 | -0.84 | -7.4% | $11.20 | $11.20 | $10.34 | 690,444 | |
| $11.35 | -2.84 | -20.0% | $14.08 | $14.19 | $10.75 | 1,722,578 | |
| $14.19 | -0.41 | -2.8% | $14.51 | $14.65 | $14.01 | 167,785 | |
| $14.60 | +0.54 | +3.8% | $14.19 | $14.68 | $13.99 | 164,905 | |
| $14.06 | +0.29 | +2.1% | $13.77 | $14.10 | $13.76 | 111,641 | |
| $13.77 | +0.45 | +3.4% | $13.24 | $13.92 | $13.20 | 178,705 | |
| $13.32 | -0.32 | -2.3% | $13.53 | $13.55 | $13.10 | 97,048 | |
| $13.64 | -0.34 | -2.4% | $13.87 | $13.95 | $13.51 | 108,637 | |
| $13.98 | +0.13 | +0.9% | $13.78 | $14.09 | $13.59 | 120,562 | |
| $13.85 | -0.15 | -1.1% | $13.93 | $14.07 | $13.66 | 179,349 | |
| $14.00 | +0.38 | +2.8% | $13.72 | $14.05 | $13.41 | 166,578 | |
| $13.62 | +0.42 | +3.2% | $13.27 | $13.64 | $13.04 | 140,555 | |
| $13.20 | -0.28 | -2.1% | $13.53 | $13.59 | $12.96 | 180,677 | |
| $13.48 | -0.23 | -1.7% | $13.75 | $13.88 | $13.20 | 218,806 |
- Ticker
- NASDAQ:RNA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Latest deck · Nov 12, 2026
Investor Presentation (November 2026)
Investor deck · 28 slides
Latest news
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Nov 12, 2026
Closed $7.51 (+0.1%) on Nov 13, 2026
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Nov 2, 2026
Closed $8.55 (+3.4%) on Nov 2, 2026
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Oct 27, 2026
Closed $8.32 (+3.4%) on Oct 27, 2026
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oct 20, 2026
Closed $8.00 (+0.3%) on Oct 21, 2026
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Sep 2, 2026
Closed $14.06 (+2.1%) on Sep 2, 2026
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Aug 13, 2026
Closed $12.84 (+4.1%) on Aug 14, 2026
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Jul 14, 2026
Closed $12.22 (0.0%) on Jul 14, 2026
Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026
Closed $13.23 (-0.3%) on May 15, 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Apr 23, 2026
Closed $13.85 (+1.4%) on Apr 23, 2026
Atrium Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 139 in all · newest Nov 12, 2026 · oldest 2020
- Decks
- 3 decks · latest Nov 12, 2026
Where Atrium Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RNA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RNA | BOATS | United States | USD |
Valuation
EV/sales −2.9× against a median of 13.6×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$113.0M USD
- P/E
- Loss
- EV/sales
- −2.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- 42.2%
- Operating margin
- −243.6%
- Net margin
- −229.7%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.24M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.4× | n/a | n/a | −146.4% | n/a | n/a |
| STCube, Inc. · KRX:052020 | US$118.4M | US$72.43M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| Curacle Co., Ltd. · KRX:365270 | US$117.6M | US$100.4M | n/a | 16.3× | n/a | 3.4× | −92.1% | 0.0× | n/a |
| PegBio Co., Ltd. Class H · HKEX:2565 | US$117.2M | US$55.97M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| enGene Therapeutics Inc. · NASDAQ:ENGN | US$116.6M | −US$149.7M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.82 |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.23M | n/a | 59,064× | n/a | 3.6× | n/a | 0.0× | n/a |
| Median of the others | US$118.3M | US$62.60M | 13.6× | 2.5× | −214.8% | 0.0× | 1.63 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 22.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.87 · 2 analysts
- Revenue, year to Dec 2026
- 38.08M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Kathleen Gallagher | Chief Executive Officer |
| Brendan Winslow | Chief Financial Officer |
| Husam S. Younis | Chief Scientific Officer |
| Rocio Martin Hoyos | Chief Strategy Officer |
| Stephanie Kenney | Chief Corporate Affairs Officer |
| Steve Hughes | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Sarah Boyce | Chair |
| Carsten Boess | Director |
| Kath Gallagher | Director |
| Kathleen Gallagher | Chief Executive Officer |
| Simona Skerjanec | Director |
| Troy Wilson | Director |
| W. Michael Flanagan | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +0.1% |
| Q2 2026 | Aug 13, 2026 · After close | +4.1% |
| Q1 2026 | May 14, 2026 · After close | −0.3% |
| Q4 2025 | Feb 23, 2026 · After close | |
| Q3 2025 | Nov 10, 2025 · After close | |
| Q2 2025 | Aug 7, 2025 · After close | |
| Q1 2025 | May 8, 2025 · After close | |
| Q4 2024 | Feb 26, 2025 · Before open | |
| Q3 2024 | Nov 7, 2024 · After close | |
| Q2 2024 | Aug 9, 2024 · After close |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | |
| Q4 2023 | Feb 28, 2024 · After close | |
| Q3 2023 | Nov 8, 2023 · After close | |
| Q2 2023 | Aug 8, 2023 · After close | |
| Q1 2023 | May 9, 2023 · After close | |
| Q4 2022 | Feb 28, 2023 · After close | |
| Q3 2022 | Nov 8, 2022 · After close | |
| Q2 2022 | Aug 9, 2022 · After close | |
| Q1 2022 | May 10, 2022 · After close | |
| Q4 2021 | Mar 1, 2022 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 28 slides | Nov 12, 2026 |
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 27 slides | August 2026 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.6M | 10.9M | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.0K | 13.1M | 10.4M |
| Cost of revenue | 4.15M | 2.78M | 2.10M | 1.39M | 639.0K | 37.6M | 14.5M | 8.44M | 32.5M | 22.7M |
| Gross profit | 18.6M | 10.9M | 7.46M | 9.22M | 9.33M | 6.79M | 2.32M | -8.06M | -19.4M | -12.4M |
| Research and development | 53.8M | 303.6M | 191.0M | 150.4M | 101.2M | 37.6M | 14.5M | 8.44M | 25.4M | 19.0M |
| Selling, general and administrative | 41.7M | 86.2M | 54.2M | 37.7M | 26.2M | 13.5M | 5.11M | 2.44M | ||
| Operating income | -76.8M | -378.9M | -235.6M | -178.9M | -118.1M | -44.3M | -17.3M | -10.5M | ||
| Depreciation and amortization | 323.0K | 2.78M | 2.10M | 1.39M | 639.0K | 373.0K | 348.0K | 383.0K | ||
| EBITDA | -76.5M | -376.2M | -233.5M | -177.5M | -117.4M | -43.9M | -17.0M | -10.1M | ||
| Interest expense | 5.69M | 639.0K | 209.0K | 7.39M | 718.0K | 0 | 0 | |||
| Income before tax | -76.8M | -322.3M | -212.2M | -174.0M | -118.0M | -44.4M | -24.7M | -11.2M | ||
| Income tax | -142.0K | 1.93M | -4.92M | -639.0K | -373.0K | 7.39M | 718.0K | |||
| Net income | -76.7M | -322.3M | -212.2M | -169.1M | -117.4M | -44.0M | -24.7M | -11.9M | ||
| Earnings per share, basic | -4.48 | -2.89 | -2.91 | -3.24 | -2.83 | -2.03 | -0.66 | -0.58 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 270.0M | 219.9M | 185.1M | 340.4M | 320.4M | 328.1M | 94.6M | 3.09M | 113.3M | 53.7M |
| Short-term investments | 1.31B | 1.28B | 410.3M | 270.3M | 85.1M | 6.68M | ||||
| Receivables | 12.4M | 28.2M | 8.62M | 3.88M | 900.0K | 1.20M | 800.0K | |||
| Inventory | -7.33M | 1 | -900.0K | -1.20M | 1 | |||||
| Current assets | 272.8M | 1.54B | 611.3M | 622.9M | 411.1M | 331.7M | 95.7M | 3.24M | ||
| Property, plant and equipment | 15.0M | 15.6M | 1.92M | 631.0K | 702.0K | 3.00M | 3.19M | |||
| Total assets | 278.4M | 1.56B | 628.6M | 638.8M | 427.6M | 333.9M | 96.9M | 3.98M | 125.1M | 62.4M |
| Accounts payable | 4.40M | 8.46M | 8.81M | 4.64M | 2.81M | 7.75M | 2.31M | 1.56M | 2.63M | 3.15M |
| Current liabilities | 41.8M | 98.0M | 80.7M | 51.9M | 29.7M | 14.6M | 10.2M | 4.62M | 12.5M | 16.1M |
| Long-term debt | 1.77M | 7.58M | 10.5M | 8.17M | ||||||
| Total debt | 3.67M | 6.80M | 9.85M | 10.7M | 11.7M | 938.0K | 4.94M | 10.3M | ||
| Total liabilities | 71.1M | 138.9M | 127.8M | 60.7M | 46.1M | 27.7M | 162.3M | 45.1M | 38.0M | 41.9M |
| Shareholders' equity | 207.3M | 1.42B | 500.8M | 578.1M | 381.4M | 306.2M | -65.4M | -41.1M | 87.1M | 20.5M |
| Shares outstanding | 17.1M | 111.6M | 73.0M | 52.2M | 41.4M | 21.7M | 37.5M | 20.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.1M | -300.9M | -119.1M | -136.3M | -94.8M | -37.1M | 2.49M | -9.65M | ||
| Capital spending | -1.45M | -7.07M | -4.23M | -2.82M | -3.74M | -1.09M | -235.0K | -49.0K | -834.0K | -309.0K |
| Free cash flow | -42.6M | -307.9M | -123.3M | -139.1M | -98.6M | -38.2M | 2.25M | -9.70M | ||
| Cash from investing | -1.45M | -854.2M | -130.1M | -190.0M | -82.5M | -7.79M | -235.0K | -49.0K | ||
| Cash from financing | 42.6M | 1.19B | 93.9M | 346.2M | 176.3M | 272.0M | 89.2M | 5.14M | 88.0M | 34.3M |
| Dividends paid | 0 | -444.0K | -106.0K | -106.0K | ||||||
| Share buybacks | 444.0K | 72.7M | 162.0K | |||||||
| Change in cash | 162.7M | 37.3M | -155.3M | 19.9M | -1.01M | 227.1M | 91.5M | -4.56M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Nov 2, 2026 | Current report | SEC |
| 8-K · Current report | Oct 27, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Oct 9, 2026 | Current report | SEC |
| 8-K · Current report | Oct 8, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
All 61 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 17, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 27, 2026 | Material contract | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| SEC STAFF ACTION | Feb 26, 2026 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Feb 26, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 24, 2026 | Other filings | SEC |
| 10-12B/A | Feb 17, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| 10-12B/A | Jan 29, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| 10-12B | Dec 10, 2025 | Other filings | SEC |
Cap table
Built by 6ix from Atrium Therapeutics, Inc.’s releases
- Common shares
- 17,105,643
- Fully diluted
- 17,105,643
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 17,105,643 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 17,105,643 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carsten Boess Other companies: Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 11, 2016); Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); Synageva BioPharma Corp (SVP, Chief Financial Officer · Nov 2, 2011 – Jun 22, 2015 · Past); Insulet Corporation (Vice President, International · May 14, 2007 – Apr 25, 2011 · Past) | Director · Since at least Nov 10, 2025 |
| Troy Wilson Other companies: Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Kura Oncology, Inc. (Chairman · Since at least Mar 6, 2015); Puma Biotechnology Inc (Director · Since at least Oct 18, 2013); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 2, 2019 · Past) | Director · Since at least Nov 10, 2025 |
| Steven George Hughes Other companies: Avidity Biosciences, Inc (Chief Medical Officer · Since at least Jan 6, 2025); Arcturus Therapeutics Holdings Inc. (Chief Development Officer · Feb 18, 2020 – Dec 18, 2020 · Past); VivoSim Labs, Inc. (Chief Medical Officer · Aug 1, 2018 – Aug 16, 2019 · Past) | Chief Medical Officer · Since at least Feb 26, 2026 |
| Simona Skerjanec Other companies: Immunic, Inc. (Director · Since at least Jul 22, 2024); Avidity Biosciences, Inc (Director · Since at least May 14, 2024) | Director · Since at least Nov 10, 2025 |
| W. Michael Flanagan Other companies: Avidity Biosciences, Inc (Chief Scientific Officer · Since at least Jan 21, 2021) | Director · Since at least Nov 10, 2025 |
| Brendan Winslow | Chief Financial Officer · Since at least Feb 26, 2026 |
| Husam S. Younis | Chief Scientific Officer · Since at least Feb 26, 2026 |
| Kath Gallagher | Director · Since at least Nov 4, 2026 |
| Kathleen Gallagher | Chief Executive Officer · Since at least Sep 22, 2026 |
| Rocio Martin Hoyos | Chief Strategy Officer · Since at least Apr 20, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Sarah Boyce | Chair · Since at least Feb 27, 2026 |
| Stephanie Kenney | Chief Corporate Affairs Officer · Since at least Apr 20, 2026 |
| Steve Hughes | Chief Medical Officer · Since at least Jul 28, 2025 |
Log in to ask 6ix AI your own questions about Atrium Therapeutics, Inc.